PALO ALTO, Calif. , May 29, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and
PALO ALTO, Calif. , May 26, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies
PALO ALTO, Calif. , May 19, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug
PALO ALTO, Calif. , May 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update.
- Six International, Investigator Sponsored Studies Initiating and Enrolling PALO ALTO, Calif. , April 30, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today
- Accelerated Assessment of MAA Previously Granted by EMA in March PALO ALTO, Calif. , April 27, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that
- HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline - Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating PALO ALTO, Calif. , April 1, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR ), focused on the development and commercialization of targeted
- Progeria MAA Submitted to EMA and Granted Accelerated Assessment PALO ALTO, Calif., March 23, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced
- Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA - Progeria NDA Submission Complete by End of March 2020 - Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif. , March 13, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
- Launch Preparation Underway for Lonafarnib in Progeria - Market Development Activities Advancing for HDV Program PALO ALTO, Calif. , Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and
- Progeria Rolling NDA Planned for Completion in 1Q 2020 - HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020 - Commercial Focus on Progeria Launch Preparation and HDV Market Building - Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020 PALO ALTO, Calif. , Jan.
- Rolling NDA Submission Planned for Completion in First Quarter 2020 - Marketing Authorization Application (MAA) to EMA Planned in First Quarter 2020 PALO ALTO, Calif. , Dec. 16, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late stage clinical biopharmaceutical company
PALO ALTO, Calif. , Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies
- Successful Pre-NDA and Pre-MAA Meetings for Progeria & Progeroid Laminopathies - Positive Phase 2 LIFT Lambda Combo Data as Late-Breaker at AASLD - First-Ever Phase 3 HDV International D-LIVR Study Enrolling and Dosing - Strong Balance Sheet with $109.9M in Cash & Investments PALO ALTO, Calif.
- >50% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 - Median Decline of HDV RNA: -3.4 Log at Week 24 - 95% of Patients Achieve >2 Log Decline in HDV RNA at Week 24 PALO ALTO, Calif. , Oct. 21, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
PALO ALTO, Calif. , Sept. 27, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Cantor
PALO ALTO, Calif. , Aug. 29, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor
-- Fourth Eiger Program Granted Breakthrough Therapy Designation PALO ALTO, Calif. , Aug. 20, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food
- First-Ever Phase 3 HDV International D-LIVR Study Enrolling - NDA and MAA filings for Progeria & Progeroid Laminopathies planned for Q4 2019 PALO ALTO, Calif. , Aug. 8, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted
PALO ALTO, Calif. , Aug. 5, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in
- Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif. , June 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the
PALO ALTO, Calif. , May 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate update at
PALO ALTO, Calif. , May 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step down as the Company's Chief Operating Officer
- First-Ever Phase 3 HDV International "D-LIVR" Study Underway - NDA and MAA filings for Progeria & Progeroid Laminopathies planned in 2019 - Strong Balance Sheet with Recent Financing Completed PALO ALTO, Calif. , May 9, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
PALO ALTO, Calif. , April 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will participate and present a
PALO ALTO, Calif. , April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share. All of the shares are being sold by Eiger.
PALO ALTO, Calif. , April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering are to be sold by Eiger.
PALO ALTO, Calif. , April 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev , JD to its Board of Directors. Mr.
- Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa - Post-treatment Endpoint Results to be Discussed with Regulatory Agencies PALO ALTO, Calif. , April 11, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and
PALO ALTO, Calif. , March 26, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will present at upcoming investor, scientific, and
- Statistically Significant Reduction in Hyperinsulinemic Hypoglycemia - Reduced Rates of Hypoglycemia and Rescue in Outpatient Setting PALO ALTO, Calif. , March 25, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted
PALO ALTO, Calif. , March 20, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate update at
- Began 2019 with $100.4 million in cash, cash equivalents & short-term investments - Enrollment of Phase 3 D-LIVR Study in HDV planned by end of 2019 - NDA and MAA filings for Progeria and Progeroid Laminopathies planned in 2019 PALO ALTO, Calif. , March 14, 2019 /PRNewswire/ -- Eiger
- 36% Durable Virologic Response at 24 Weeks Post-Treatment PALO ALTO, Calif. , March 13, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a
PALO ALTO, Calif. , March 11, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate update at
PALO ALTO, Calif. , Feb. 27, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr. Stephana Patton as the Company's General Counsel,
Expanded Patent Portfolio Now Includes U.S., Europe and Japan PALO ALTO, Calif. , Feb. 6, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today that the European
PALO ALTO, Calif. , Feb. 4, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has been granted for results of the Phase 2 PREVENT study at ENDO 2019 in
PALO ALTO, Calif. , Jan. 7, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray , MS, RAC to its Board of Directors. Ms.
- Survival Benefit in Children with Progeria Published in JAMA 2018 - NDA Filing Planned in 2019 PALO ALTO, Calif. , Dec. 19, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases,
- Phase 3 HDV "D-LIVR" International Study Initiating PALO ALTO, Calif. , Dec. 18, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the European Medicines
- Phase 3 HDV "D-LIVR" International Study Initiating PALO ALTO, Calif. , Dec. 17, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug
-- Late Stage Rare and Ultra-Rare Disease Pipeline Advancing -- >$100M in Cash Available to Achieve Key Milestones PALO ALTO, Calif. , Dec. 11, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and
PALO ALTO, Calif. , Dec. 4, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on December 11, 2018 from 12:00 PM to 2:30 PM EST at the
PALO ALTO, Calif. , Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the appointment of Sri Ryali as the company's Chief Financial Officer. Mr.
- Plans to File NDA in 2019 PALO ALTO, Calif. , Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the U.S.
PALO ALTO, Calif. , Nov. 19, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory , President and CEO, will present a corporate update at the 30 th Annual Piper
- HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019 - Over $100 million in cash to advance late stage rare disease pipeline PALO ALTO, Calif. , Nov. 9, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of
PALO ALTO, Calif. , Oct. 23, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the accelerated development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today the pricing of its
PALO ALTO, Calif. , Oct. 22, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that it has commenced an underwritten public offering of its common stock.
- Designation Enables Priority Review Voucher Eligibility Upon NDA Approval PALO ALTO, Calif. , Oct. 22, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S.
PALO ALTO, Calif. , Oct. 18, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the Eiger management team will participate and host 1:1 investor meetings at the BTIG Biotech
- Lambda Antiviral Activity Demonstrated in HDV Infection - Currently Dosing Lambda in Combination with Lonafarnib in HDV Infection PALO ALTO, Calif. , Oct. 17, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced positive data with Pegylated Interferon Lambda
PALO ALTO, Calif. , Oct. 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced Phase 2 ULTRA study results in primary and secondary lymphedema of the lower limb demonstrated
- Primary and Secondary Endpoints Achieved with Statistical Significance - Avexitide Treatment Reduces Hypoglycemia and Hyperinsulinism PALO ALTO, Calif. , Oct. 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted
PALO ALTO, Calif. , Sept. 25, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present at two investor conferences in
D-LIVR Study: First-Ever Registration Study for Chronic HDV Infection PALO ALTO, Calif. , Sept. 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the receipt of written
- Company advancing plans to file NDA for Lonafarnib in Progeria PALO ALTO, Calif. , Sept. 4, 2018 /PRNewswire/ -- Today, Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a company focused on the development and commercialization of targeted therapies for rare diseases, announced it has received
PALO ALTO, Calif. , Aug. 27, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that members of the Eiger management team will participate in multiple investor conferences in
PALO ALTO, Calif. , Aug. 13, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study. PREVENT is a multi-center, placebo-controlled
PALO ALTO, Calif. , Aug. 10, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and six months ended June 30, 2018 and provided a business
PALO ALTO, Calif. , Aug. 7, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO, will present a corporate update at the 2018 Wedbush PacGrow
PALO ALTO, Calif. , Aug. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today first patient enrolled in the Phase 2 LIFT Study conducted within the National Institutes of
PALO ALTO, Calif. , July 31, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has received the Notice of Allowance from the United States Patent and Trademark Office
PALO ALTO, Calif. , June 4, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation from the Phase 2 LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis
PALO ALTO, Calif. , May 30, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory , President and CEO, will present a corporate update at Jefferies 2018 Global
PALO ALTO, Calif. , May 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today the pricing of its previously announced underwritten
PALO ALTO, Calif. , May 23, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that it has commenced an underwritten public offering
- Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication PALO ALTO, Calif. , May 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases,
- Hepatitis Delta Virus (HDV) Program Moving into Phase 3 - Phase 2 Clinical Results Planned Across All Pipeline Programs in Second Half 2018 - Existing Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , May 11, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
PALO ALTO, Calif. , April 17, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program presented at The International Liver Congress™ 2018, in
PALO ALTO, Calif. , April 2, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that Eiger will participate at upcoming investor, scientific, and orphan drug conferences in
PALO ALTO, Calif. , March 26, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2, multi-center study of subcutaneous (SC) exendin 9-39 in
- Phase 3 D-LIVR Trial Planned to Initiate in Second Half 2018 PALO ALTO, Calif. , March 21, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today positive FDA guidance from a
- Hepatitis Delta Virus Program Moving into Phase 3 in 2018 - Phase 2 Clinical Results Planned from Three Pipeline Programs in 2018 - Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , March 12, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
PALO ALTO, Calif. , March 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
PALO ALTO, Calif. , March 5, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program will be presented at The International Liver Congress™ meeting in Paris, France ,
PALO ALTO, Calif. , Feb. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
- End of Phase 2 Meeting Scheduled for HDV in February 2018 - Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif. , Jan. 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare
PALO ALTO, Calif. , Jan. 8, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors. Mr.
- ULTRA Study Data Expected in Second Half 2018 PALO ALTO, Calif. , Jan. 4, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 ULTRA study.
PALO ALTO, Calif. , Jan. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian , MD, PhD, MBA as Chief Operating Officer and Executive Medical Officer.
PALO ALTO, Calif. , Jan. 2, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory , President and CEO, will present a corporate update at Biotech Showcase ™
PALO ALTO, Calif. , Nov. 13, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate update at Jefferies
-Clinical Results Planned in Each of Four Orphan Disease Programs by 4Q 2018 -Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , Nov. 9, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare
PALO ALTO, Calif. , Nov. 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory , President and CEO of Eiger, will participate and present in three upcoming
PALO ALTO, Calif. , Oct. 31, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the closing of its underwritten public offering of
PALO ALTO, Calif. , Oct. 27, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of
PALO ALTO, Calif. , Oct. 26, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market
PALO ALTO, Calif. , Oct. 23, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive interim 24-week data with pegylated interferon lambda (Lambda) in the Phase 2 LIMT HDV ( L ambda I nterferon M ono T herapy in H epatitis D elta V irus) Study presented at the
PALO ALTO, Calif. , Oct. 2, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced that two abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Washington DC , October 20 to 24, 2017 .
- Company Advancing Multiple Programs in Orphan Disease Pipeline PALO ALTO, Calif. , Sept. 18, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh , MD to its
PALO ALTO, Calif. , Sept. 5, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan designation for pegylated
PALO ALTO, Calif. , Aug. 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
- Five Phase 2 Programs Advancing in Multiple Orphan Indications - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif. , Aug. 14, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies
PALO ALTO, Calif. , Aug. 8, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
PALO ALTO, Calif. , July 27, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif. , July 24, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced completion of enrollment of the Phase 2
PALO ALTO , Calif. and SAN DIEGO , June 29, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), announced today an agreement to sell to Theragene Pharmaceuticals, Inc. , a private biotechnology company, a non-strategic asset, Mydicar ® (rAAV1-SERCA2a).
- Company Prepares to Advance Orphan Disease Pipeline PALO ALTO, Calif. , June 14, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian , MD, PhD, MBA to
- Novel Liquid Formulation of Subcutaneous Exendin 9-39 Highlighted PALO ALTO, Calif. , June 12, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced positive data from the Phase 2
PALO ALTO, Calif. , June 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced completion of enrollment of the Phase 2 multiple-ascending dose (MAD) study evaluating subcutaneous (SC)
PALO ALTO, Calif. , May 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
- Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema PALO ALTO, Calif. , May 17, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies of ubenimex in
- Phase 2 LIBERTY Data Expected First Quarter 2018 PALO ALTO, Calif. , May 15, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 LIBERTY
- Five Phase 2 Programs in Four Orphan Indications Progressing - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif. , May 12, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for
PALO ALTO, Calif. , May 8, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced HDV/HBV co-infection prevalence data from an International Classification of Diseases (ICD) analysis presented at Digestive Disease Week (DDW) in Chicago , Illinois. Results from two
- Phase 2 LIBERTY Study Update for Ubenimex in PAH PALO ALTO, Calif. , May 4, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, will host a key opinion leader lunch to address the need for
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling PALO ALTO, Calif. , May 3, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the U.S.
PALO ALTO, Calif. , April 24, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced that an abstract describing prevalence of hepatitis delta virus (HDV) in the U.S. will be presented at Digestive Disease Week (DDW) in Chicago, Illinois , May 6 to 9, 2017 .
PALO ALTO, Calif. , April 21, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional supportive and encouraging lonafarnib (LNF) data from the LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program presented at The International Liver
- Novel Liquid Formulation of Exendin 9-39 Advancing PALO ALTO, Calif. , April 18, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the appointment of Lisa Porter , M.D.
PALO ALTO, Calif. , April 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program will be presented at the European Association for the Study of the Liver (EASL)
- Five Phase 2 Programs in Four Orphan Indications - Multiple Value-Creating Events Across Programs Expected in Next 12-18 Months PALO ALTO, Calif. , March 23, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies
PALO ALTO, Calif. , Jan. 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
PALO ALTO, Calif. , Jan. 4, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that it has completed a $25 million debt financing transaction with Oxford Finance LLC ("Oxford"), a
First-in-class inhibitor of LTB4 targeting disease modification in PAH PALO ALTO, Calif. , Jan. 3, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that the first patient has completed
PALO ALTO, Calif. , Nov. 21, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a clinical stage biopharmaceuticals company focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will
- Update on Data Presented and Analyst Meeting through Monday Evening PALO ALTO, Calif. , Nov. 14, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced presentation of additional data from the LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus)
- Data Presented through Monday Morning PALO ALTO, Calif. , Nov. 14, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced an update on presentations of data from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program presented as of today at
- Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 - Eiger Hosted LOWR HDV Program Key Opinion Leader Review at AASLD 2016 - Four Product Candidates in Four Orphan Indications Continuing to Advance PALO ALTO, Calif.
- Collaboration with ARUP Laboratories and Hepatitis B Foundation - HDV viral load assay now available in U.S. PALO ALTO, Calif. , Oct. 24, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif. , Oct. 19, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient was dosed in the
PALO ALTO, Calif. , Oct. 17, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency (EMA) has granted orphan designation to exendin 9-39 for the treatment
PALO ALTO, Calif., October 13, 2016 — Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in
PALO ALTO, Calif. , Sept. 7, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the completion of dosing of LOWR HDV – 4 ( LO
PALO ALTO, Calif. , Sept. 6, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will
PALO ALTO, Calif. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) has been invited to present at the 2016 Gateway Conference being held on September 7-8, 2016 at the Four Seasons Hotel San Francisco . Eiger BioPharmaceuticals management is scheduled to present on
PALO ALTO, Calif. , Aug. 18, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of
PALO ALTO, Calif. , Aug. 17, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market
- Four Product Candidates in Four Orphan Indications Advancing Toward Near-Term Milestones PALO ALTO, Calif. , Aug. 10, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a
PALO ALTO, Calif. , Aug. 8, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory , President and CEO of Eiger, will present a corporate overview and business
Novel first-in-class inhibitor of LTB(4) production targeting disease modification PALO ALTO, Calif. , July 25, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first
Novel first-in-class inhibitor of LTB(4) targeting disease modification PALO ALTO, Calif. , July 18, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first patient
PALO ALTO, Calif., July 6, 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the Cantor Fitzgerald 2 nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 9:00 am ET at Le
Oral Presentation at American Diabetes Association Meeting in New Orleans, LA PALO ALTO, Calif. , June 13, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the presentation of positive
PALO ALTO, Calif. , May 16, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and financial results for the three months ended March 31, 2016. Recent
Novel first-in-class GLP-1 antagonist targeted for rare hypoglycemic condition PALO ALTO, Calif. , May 10, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first
PALO ALTO, Calif. , May 3, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a biopharmaceutical company focused on the development and commercialization of targeted therapies for Orphan diseases, announced today the appointment of Debra Odink, PhD as the Company's Senior Vice
Including Rights for All Indications and Associated Patents PALO ALTO, Calif. , April 20, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) announced today that it has licensed Pegylated Interferon Lambda-1a ("Lambda"), a novel, well-characterized, first in class Type III
PALO ALTO, Calif. , April 4, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc , (NASDAQ: EIGR) announced today that its Board of Directors has appointed Charles J. "Chuck" Bramlage as a member of the Board. Mr. Bramlage is a pharmaceutical industry veteran with extensive experience in marketing,
PALO ALTO, Calif. , March 30, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) today announced that abstracts from its Hepatitis Delta Virus (HDV) development program will be presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain ,
PALO ALTO, Calif., March 28, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product status to ubenimex for the treatment of pulmonary arterial hypertension (PAH).
Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease Programs PALO ALTO, Calif. , March 22, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. ( NASD : EIGR) today announced completion of its merger with Celladon Corporation
